Background information

Porcine pseudorabies (PR) is an acute infectious disease caused by the Porcine Pseudorabies virus (PRV). Infection manifests primarily in piglets with clinical symptoms such as high fever, diarrhea, and vomiting, accompanied by an extremely high mortality rate; boars develop orchitis leading to impaired semen quality; while sows experience abortion, stillbirths, or mummified fetuses. The prevalence of this disease poses significant threats to the swine industry.

In the late 1970s, the Bartha-K61 strain vaccine was introduced and widely adopted in China, leading to effective control of porcine pseudorabies virus (PRV) outbreaks, with many pig farms achieving complete eradication of PRV. Since 2012, however, PRV variants have emerged and spread across the country, posing new challenges to PRV prevention and control efforts. Based on field experience and clinical trials, the Bartha-K61 vacine has proven insufficiently protective against these variants, necessitating urgent development of novel vaccines to curb such outbreaks.

To address these challenges,Jiangsu Nanong High-Tech Co.,Ltd.collaborated with Nanjing Agricultural University to isolate the highly virulent PRV variant strain ZJ01 and successfully constructed the gene-engineered strain ZJ011G with deletions in the gE/gl genes using genetic engineering techniques. Based on this strain, an inactivated vaccine targeting the PRV variant was developed. The vaccine produced with strain ZJ 011G provides robust clinical protection for pig populations while effectively preventing the transmission of pseudorabies virus within pig farms, playing a crucial role in the prevention, control, and eradication of pseudorabies in livestock operations.

Product Features of JingWeiQing

The Vaccine Strain Was Constructed Using a Circulating Variant of the PRV Virus.

The highly virulent strain ZJ01 was isolated from a pig farm. Animal experiments demonstrated that its virulence was significantly enhanced compared to classical PRV strains, with altered antigenicity. Building on this foundation, the gene engineering technique was successfully employed to construct the ZJ011G strain,which lacks both the gE and gl genes. This development provides robust product and technical support for the prevention and control of porcine pseudorabies in China under new circumstances.

The Application of the ZJ011G Strain Vaccine Is Suitable for Identification Testing, Facilitating Purification Processes.

The vaccine strain exhibits deletion of the gE/gl genes. The inactivated vaccine prepared using this strain maintains excellent immunogenicity while preventing viral reactivation, demonstrating superior safety profile. Additionally, it enables differential diagnosis of pseudorabies virus gE antibodies in pigs; elimination of gE antibody-positive pigs is essential for herd purification.

Highly sensitive clonal cell lines were employed to achieve high viral titers.

Through cell cloning and screening, a cell line highly sensitive to the PRV ZJ011G strain was obtained, with a viral culture titer reaching 10 9.0TCID50/ml.

The Antigen Is Further Purified Through Chromatographic Purification.

The pseudorabies virus was purified by chromatography, with impurity proteins removed, resulting in a pure antigen and a vaccine that is safe and free from stress responses.

The use of imported adjuvants results in a prolonged duration of immunity.

This product utilizes the FrenchISA15A series adjuvant, featuring convenient injection and excellent needle penetration. Effective neutralizing antibody titers can be achieved within 3 weeks of immunization, with significantly elevated antibody levels post-enhanced immunization. The duration of effective neutralizing antibody titers remains stable for no less than 18 weeks.

Recommended Immunization Schedul

Immunization method: Intramuscular injection in the neck region
Immunization schedule: For pigs aged ≥21 days, administer the initial dose at 1 mL per head, followed by a booster dose at the same dosage after 21 days.
For sows, administer the initial dose 40–45 days before farrowing at 4 mL per head, followed by a booster dose at the same dosage after 21–28 days.